Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.

Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.

Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.

Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.

Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.

Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.

Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.

Abstract: A silicon nanowire bio-chip structure and a manufacturing method thereof. The structure comprises a semiconductor substrate (1), a SiO2 insulating layer (2) formed on the semiconductor substrate, a polysilicon layer (3) formed on the SiO2 insulating layer (2) and a structural layer formed on the polysilicon layer (3); wherein, the polysilicon layer (3) comprises a patterned silicon nanowire array (4); the structural layer includes a SiON layer, a TaN and/or Ta2O5 layer (6) from bottom to top, the TaN and/or Ta2O5 layer only covers surface of each silicon nanowire in the silicon nanowire array. The silicon nanowire array is prevented from being polluted during preservation and use, and the pollutants of Na ions, K ions, Fe ions, Cu ions and Ca ions as well as the effects of chemical factors including the PH value are blocked during biological detection, thereby achieving the high stability of detection.

Abstract: A silicon nanowire bio-chip structure and a manufacturing method thereof. The structure comprises a semiconductor substrate (1), a SiO2 insulating layer (2) foamed on the semiconductor substrate, a polysilicon layer (3) foamed on the SiO2 insulating layer (2) and a structural layer formed on the polysilicon layer (3); wherein, the polysilicon layer (3) comprises a patterned silicon nanowire array (4); the structural layer includes a SiON layer, a TaN and/or Ta2O5 layer (6) from bottom to top, the TaN and/or Ta2O5 layer only covers surface of each silicon nanowire in the silicon nanowire array. The silicon nanowire array is prevented from being polluted during preservation and use, and the pollutants of Na ions, K ions, Fe ions, Cu ions and Ca ions as well as the effects of chemical factors including the PH value are blocked during biological detection, thereby achieving the high stability of detection.